Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial

Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...

Merck stock jumps as Keytruda combo trials boost cancer pipeline

The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...

Kelun, Merck's lung cancer combo improves survival in late-stage China trial

May 21 () - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment combined with partner Merck's ...
BioSpace

Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival

Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...

FDA approves Enhertu as neoadjuvant, adjuvant treatment for breast cancer

The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the ...
Le Lézard

Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline

Bristol Myers Squibb today announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 29 ? June ...
Precision Medicine Online

Lung Cancer Patients Take a Hit of Inhaled Gene Therapies in Trials

Krystal Biotech is the furthest along in pursuing this approach and is ironing out details of a registrational trial for its ...